uniQure NV (NASDAQ:QURE) has been assigned an average rating of “Buy” from the eleven analysts that are covering the company. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $27.75.
Several research analysts recently issued reports on QURE shares. HC Wainwright started coverage on shares of uniQure NV in a research note on Thursday, August 4th. They issued a “buy” rating and a $21.00 price target for the company. WallachBeth Capital reduced their price objective on shares of uniQure NV from $60.00 to $35.00 and set a “buy” rating for the company in a research note on Wednesday, June 15th. Cowen and Company restated a “buy” rating on shares of uniQure NV in a research note on Tuesday, June 14th. Leerink Swann restated a “buy” rating on shares of uniQure NV in a research note on Sunday, June 12th. Finally, Piper Jaffray Cos. restated a “buy” rating on shares of uniQure NV in a research note on Monday, June 13th.
Shares of uniQure NV (NASDAQ:QURE) traded down 3.41% during mid-day trading on Thursday, hitting $7.64. 88,186 shares of the company were exchanged. The company’s market capitalization is $191.99 million. uniQure NV has a 52 week low of $6.68 and a 52 week high of $22.79. The company has a 50 day moving average of $8.05 and a 200 day moving average of $10.01.
uniQure NV (NASDAQ:QURE) last issued its quarterly earnings results on Thursday, August 25th. The company reported ($0.87) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.89) by $0.02. uniQure NV had a negative net margin of 537.62% and a negative return on equity of 61.96%. Equities analysts anticipate that uniQure NV will post ($3.71) earnings per share for the current year.
Several hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. increased its position in uniQure NV by 68.5% in the second quarter. JPMorgan Chase & Co. now owns 14,174 shares of the company’s stock worth $104,000 after buying an additional 5,760 shares during the last quarter. TFS Capital LLC increased its position in uniQure NV by 3.0% in the second quarter. TFS Capital LLC now owns 15,156 shares of the company’s stock worth $112,000 after buying an additional 437 shares during the last quarter. Princeton Alpha Management LP acquired a new position in uniQure NV during the second quarter worth about $120,000. Fox Run Management L.L.C. acquired a new position in uniQure NV during the second quarter worth about $122,000. Finally, Acrospire Investment Management LLC increased its position in uniQure NV by 355.2% in the second quarter. Acrospire Investment Management LLC now owns 17,298 shares of the company’s stock worth $127,000 after buying an additional 13,498 shares during the last quarter. Hedge funds and other institutional investors own 32.38% of the company’s stock.
uniQure NV Company Profile
uniQure N.V. is engaged in the field of gene therapy. The Company is engaged in the discovery, development and commercialization of gene therapies. It has a technology platform that uses as the basis for collaborative product candidates across approximately three therapeutic focus areas, such as Liver/Metabolic Disease, Central Nervous System (CNS) Disease and Cardiovascular Disease.
Receive News & Ratings for uniQure NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure NV and related companies with MarketBeat.com's FREE daily email newsletter.